Home > Journals > Minerva Urology and Nephrology > Past Issues > Minerva Urology and Nephrology 2022 October;74(5) > Minerva Urology and Nephrology 2022 October;74(5):508-17

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   

Minerva Urology and Nephrology 2022 October;74(5):508-17

DOI: 10.23736/S2724-6051.22.04847-9

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

Androgen deprivation therapy and cardiovascular risk in prostate cancer

Cosimo DE NUNZIO 1 , Cristian FIORI 2, Ferdinando FUSCO 3, Andrea GREGORI 4, Vincenzo PAGLIARULO 5, Filippo ALONGI 6, 7

1 Division of Urology, Sapienza University, Rome, Italy; 2 Division of Urology, Department of Oncology, School of Medicine, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy; 3 Unit of Urology, Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy; 4 Unit of Urology, Sacco Hospital, Milan, Italy; 5 University Hospital of Bari, Bari, Italy; 6 Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy; 7 University of Brescia, Brescia, Italy



Androgen-deprivation therapy (ADT), with or without palliative local treatments, is the standard of care for many patients with locally-advanced and/or metastatic prostate cancer. However, the possible cardiovascular (CV) risks associated with gonadotropin-releasing hormone (GnRH) antagonists and agonists continue to be the subject of concern, especially in a patient population that may already be at increased CV risk. The present review provides a narrative summary of the evidence regarding the CV risks associated with GnRH antagonists and agonists from randomized clinical trials (RCTs), real-world evidence, and meta-analyses. From RCTs, it appears clear that there is a direct class effect for CV risk in patients with prostate cancer being administered GnRH agonists and antagonists, with the latter being associated with reduced CV risk. Real-world data and the available meta-analyses largely indicate that CV risk is lower with GnRH antagonists than with GnRH agonists. A review of the pathophysiological mechanisms of gives further support to the possibility that GnRH antagonists are associated with lower CV risk than agonists. It can be highlighted that when treating patients with advanced or metastatic prostate cancer it is important to screen for underlying comorbidities prior to choosing the most appropriate therapy; moreover, patients should be closely monitored for factors associated with CV risk in order to optimize outcomes. Further studies are needed to define the most appropriate treatment according to the individual patient characteristics.


KEY WORDS: Therapy; Cardiovascular diseases; Prostatic neoplasms

top of page